Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Practice Point
Nature Reviews Clinical Oncology 2, 68–69 (1 February 2005) | doi:10.1038/ncponc0080
Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Abstract
Tannock IF et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502–1512 Synopsis Background Mitoxantrone (Novantrone|[reg]|; OSI, Melville, NY) plus a corticosteroid for hormone-refractory prostate cancer enhances quality of life and pain relief, but does not prolong survival.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
